Physician profile
Samir Mehta
NPI 1154909430
$1,257.02
in general payments reported to CMS, 2019-2025
13 companies · $644 in 2025
The $644 reported for 2025 was more than what 83% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $614 · 2025: $644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,257.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $468.19 | 2024-2025 | Emblem Mri S-Icd, Rotablator Rotational Atherectomy System Console Kit, General - Therapies |
| Cvrx, INC. | $153.26 | 2024 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $134.54 | 2024 | |
| Abiomed | $106.01 | 2025 | |
| Bridgebio Pharma, INC. | $102.00 | 2025 | Attruby |
| Amgen INC. | $90.44 | 2024 | Tavneos |
| Genzyme Corporation | $60.64 | 2024-2025 | |
| Medtronic, INC. | $31.06 | 2024 | Azure Xt Dr Mri Surescan |
| Novo Nordisk INC | $27.75 | 2025 | Wegovy |
| Abbott Laboratories | $23.27 | 2025 | Perclose Prostyle |
| Teleflex LLC | $21.32 | 2025 | Arrow |
| Terumo Medical Corporation | $20.83 | 2024 | Angio-Seal |
| Chiesi USA, INC. | $17.71 | 2025 | Cleviprex, Kengreal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.